Roxanne is a corporate strategy advisor of Elixiron Immunotherapeutics, and Adjunct Professor of Department of Genetics, Stanford University. She brings to Elixiron more than two decades of industry experience in pharmaceutical and biotech management. Previously, Roxanne was Vice President of Operations & Business Development at Nuredis, Inc. Prior to Nuredis, she was a co-founder and Chief Executive Officer of Affinita Biotech, Inc., where she successfully raised $35 million funding and kick-started the preclinical development of a therapeutic antibody for cancer treatment. In addition to her former role at Affinita, Roxanne served as Director of External Collaborations at MedImmune, LLC. (from 2012 to 2015) and Director of External Discovery & Scientific Operation, at GSK R&D Center in Shanghai (from 2010 to 2012). Her responsibilities included design and execution of partnering strategies and establishment of multiple collaborations with CRO and academic institutes. Prior to joining GSK, Roxanne was Vice President of R&D Adlyfe, Inc. where she oversaw the development of a technology platform for detection of pathogenic mis-folding proteins in patients with neurodegenerative diseases. Prior to Adlyfe, Roxanne served as Chief Scientific Officer at Functional Genetics, Inc. and held various research positions in Human Genome Sciences, Inc. Roxanne received her Ph.D. in Pharmaceutical Chemistry from University of California, San Francisco (UCSF) and completed two postdoctoral fellowships, one at UCSF and the second at National Cancer Institute, Bethesda.